Source Fact: Financial Supervisory Service DART / 2025-07-11
Disclosure Type: Ruling on Lawsuit (Amendment)
💡 3-Second Summary
Celltrion has amended its public filing after receiving the official written judgment for the COVID-19 diagnostic kit lawsuit against Humasis, which orders Celltrion to pay approximately KRW 12.7 billion in the first instance. Celltrion announced its decision to appeal.
📊 1. [Key Disclosure Details & Major Figures]
- Case Name: Product Payment, etc. (Suwon District Court Anyang Branch, Case No. 2023Gahap100211)
- Plaintiff: Humasis Co., Ltd.
- First Instance Judgment (Amount Defendant Celltrion is Ordered to Pay to Plaintiff Humasis):
- Judgment Amount: KRW 12,710,724,105 (Approx. KRW 12.7B, representing 0.07% of Celltrion’s equity)
- Breakdown:
- USD 2,094,300 (Approx. KRW 2.85B based on the exchange rate of USD/KRW 1,359.40 on July 3, 2025) plus delinquency interest
- KRW 9,863,732,685 plus delinquency interest
- Delinquency Interest Rate: 6% per annum up to July 3, 2025, and 12% per annum thereafter until fully paid
- Litigation Costs Allocation: 90% to be borne by Plaintiff (Humasis) and 10% by Defendant (Celltrion)
- Celltrion’s Counterclaim (Damages, etc.) Judgment Details (Listed under Important Matters):
- Case Name: Claims for Damages, etc. (Plaintiff: Celltrion / Defendant: Humasis)
- Judgment Amount (Amount Defendant Humasis is Ordered to Pay to Plaintiff Celltrion): KRW 3,887,761,421 (Approx. KRW 3.9B)
- Breakdown:
- USD 2,587,189.29 (Approx. KRW 3.52B based on USD/KRW 1,359.40) plus delinquency interest
- KRW 370,736,301 plus delinquency interest
- Delinquency Interest Rate: 6% per annum up to July 3, 2025, and 12% per annum thereafter until fully paid
- Litigation Costs Allocation: 95% to be borne by Plaintiff (Celltrion) and 5% by Defendant (Humasis)
- Reason for Amendment: To reflect the exact terms and details of the written judgment officially delivered by the court on July 11, 2025, following the ruling on July 3, 2025.
- Future Action: Celltrion intends to appeal the decision and actively respond through legal procedures.
📈 2. [Expert Perspective: What This Means for Investors]
This amended filing details the first-instance court ruling regarding outstanding payments and damages associated with a pandemic-era COVID-19 diagnostic kit joint business agreement between Celltrion and Humasis. The court-ordered payment of approximately KRW 12.7 billion accounts for 0.07% of Celltrion’s consolidated equity (approx. KRW 17.58T). Consequently, this ruling is highly unlikely to pose any immediate or material risk to the company’s overall financial health or operational liquidity.
Importantly, the payment obligation of approximately KRW 12.7 billion and the court-ordered allocation of litigation costs (under which Celltrion bears 10%) are distinct legal concepts. Even though Celltrion’s share of litigation costs is limited to 10%, this cost allocation only applies to administrative fees and legal expenses incurred during the proceedings; it does not offset or reduce the principal payment obligation of KRW 12.7 billion. Similarly, while Celltrion was awarded approximately KRW 3.9 billion in its countersuit, these two rulings remain legally separate until finalized. Since Celltrion has committed to an appeal, the actual cash outflow and final financial impact will depend on the decisions of the appellate courts.
📝 Editor’s Comment (by K-STOCK Editor)
The legal dispute with Humasis arising from the termination of the COVID-19 diagnostic kit business has entered a more concrete stage with the delivery of the first-instance written judgment. This amendment details the mutual payment obligations determined by the court. However, since Celltrion has announced its decision to appeal, a final resolution of this dispute is expected to take significant time.
For global investors, the primary variable to monitor is the potential financial impact of prolonged litigation. While the principal judgment amount is small relative to Celltrion’s balance sheet, the ruling carries substantial delinquency interest rates—6% per annum up to the judgment date and 12% per annum thereafter until fully settled. Therefore, the timing of the final resolution and the outcome of the appeal will determine the eventual size of the financial liability.
Additionally, investors should monitor whether and to what extent Celltrion recognizes litigation provisions in its upcoming quarterly financial statements based on this first-instance outcome. Tracking how these legacy litigation risks are reflected in the quarterly reports will be necessary to assess any temporary impacts on the company’s earnings.
📢 Disclaimer & Source
Source: This content has been structured and rewritten based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Inquiries: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
